COVID-19 Vaccines and Effective Communications Strategies

The U.S. distribution of safe and efficacious vaccines to prevent COVID-19 has increased exponentially since December 2020. The average daily rates of vaccines administered in the U.S. has reached 3.3 million in April. On April 14, the U.S. reached more than 194.8 million total doses administered with 76.7 million persons (23.1% of the total U.S….

Read More →

Current Status of COVID-19 Vaccines Rollout Nationwide: March 2021 Update for the Attorney General Community

The distribution of three safe and efficacious vaccines to prevent COVID-19 has continued to ramp up both globally and domestically. Here in the U.S., average daily rates of vaccines administered has increased from 1.5 million at the end of February to close to 2.5 million in March. On March 24, the U.S. reached over 130…

Read More →

The Defense Production Act and Implications for the COVID-19 Vaccine Rollout

Since the U.S. Food and Drug Administration (FDA) issued authorizations for the Pfizer-BioNTech and Moderna vaccines to prevent COVID-19, millions of doses of both of these safe and effective vaccines have been administered throughout the United States. On February 27, the FDA authorized a third vaccine from Janssen, a subsidiary of Johnson & Johnson. An…

Read More →

Current Status of COVID-19 Vaccines Rollout Nationwide: February 2021 Update for the Attorney General Community

In December 2020, the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna vaccines to prevent COVID-19. Within twenty-four hours of each authorization, doses began shipping across the country to every state, marking significant milestones in the national response to the COVID-19 pandemic. Since then, over sixty-six million…

Read More →

NAGTRI Resources and Training on the Legal and Policy Implications for COVID-19 Vaccines

On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine to prevent COVID-19 among individuals 16 years of age and older. The following week, the FDA granted a separate EUA for the Moderna COVID-19 vaccine for those 18 years and older.  Within twenty-four hours…

Read More →